ARTICLE | Finance
X marks the spot
Gemin X raises $16M D round to fund Phase IIb lung cancer trial
April 26, 2010 7:00 AM UTC
Investors in oncology play Gemin X Pharmaceuticals Inc. are hoping last week's $16 million series D round, with an optional additional $4 million, will be enough to get the company through Phase IIb data.
Existing investors Caxton Advantage Life Sciences Fund and Sanderling Venture Partners led the recent round. The company did a $38 million C round in 2008...